Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.

Ruben Niesvizky,Vania Hungria,Joy Ho,Aleksandr Suvorov,Darrell White,Dina Ben-Yehuda,Lifen Zhou,Karim Iskander,Laura Rosiñol

Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.

2017

Ruben Niesvizky
Vania Hungria
Joy Ho
Aleksandr Suvorov
Darrell White
Dina Ben-Yehuda
Lifen Zhou
Karim Iskander
Laura Rosiñol

8041Background: PN is a dose-limiting toxicity for some anti-MM agents, such as the proteasome inhibitor (PI) bortezomib (V). Carfilzomib (K), a novel irreversible PI associated with low PN, was ev...

Keywords:

Refractory Multiple Myeloma
Peripheral neuropathy
Oncology
Carfilzomib
Pathology
Internal medicine
Medicine
Toxicity
Bortezomib
in patient
phase iii trials
Proteasome inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations